Did You Lose Money Investing in uniQure (QURE)?
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE).
On September 29, 2026, uniQure’s shares declined significantly after the Company reported updated 48-month data for ifezuntirgene inilparvovec, also known as AMT-130, its investigational gene therapy for Huntington’s disease.
On this news, uniQure’s stock price was down more than 35% during intraday trading on September 29, 2026.
uniQure Investors: Contact Kehoe Law Firm
If you purchased uniQure stock and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the investigation and your potential legal rights.
For a free, no-obligation legal evaluation, contact:
Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.
There is no cost or obligation to speak with the firm, and there are no upfront fees or litigation costs. We handle class action matters on a contingency-fee basis. Any attorneys’ fees or expenses sought in connection with a recovery are subject to court approval.
SEND US A MESSAGE
Contact Us
ADDRESS
Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103